InterVenn Receives Foundational Patent, CLIA Lab Certification to Develop Clinical Glycoproteomics Solutions

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--InterVenn receives CLIA certification and is issued a new patent as it develops the world’s first glycoproteomics-based LDT

Click to view original post